Singaporean biotech company MiRXES has applied for listing in Hong Kong, and may become the first overseas company to be listed under HKEX’s new listing mechanism for specialist technology companies.
The GASTROClear, test kit developed by MiRXES, is the world’s first cell-based blood test kit approved for sale to detect early gastric cancer.
MiRXES Co-founder and CEO Zhou Lihan said Hong Kong has a more mature ecosystem for listing biotech companies, and hoped to capitalize on the professional healthcare and biotech investor base in mainland China and Hong Kong.